Cowen and Company’s Krystal Biotech KRYS Stock Holding History

Cowen and Company’s Portfolio KRYS Stock Details KRYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-16,634	Closed	-$2.06M	–	700
2023 Q4	$2.06M	Buy	+16,634	New	+$1.84M	0.14%	111

Other funds holding KRYS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Cowen and Company's KRYS Position: Q1 2024 in Review

Cowen and Company sold out of Krystal Biotech (KRYS) in Q1 2024, closing a stake of 16,634 shares — an estimated $2.06M sold.

Cowen and Company first reported a position in KRYS in Q4 2023 and held it in 1 quarter. The position peaked at $2.06M in Q4 2023. 234 funds tracked by Wall St. Rank hold KRYS as of Q1 2024.

Cowen and Company reported no remaining Krystal Biotech position as of Q1 2024 after selling out during the quarter.
Cowen and Company sold 16,634 Krystal Biotech shares in Q1 2024, an estimated $2.06M.
Cowen and Company first reported a position in Krystal Biotech in Q4 2023 and held it in 1 quarter.
Cowen and Company's Krystal Biotech position peaked at $2.06M in Q4 2023.
234 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2024.

Based on Cowen and Company's 13F filing for Q1 2024, filed 3 May 2024.